CRISPR makes prostate cancer vulnerable to immunotherapy
Scientists used CRISPR to modify RNA in prostate cancer cells, making them more visible to the immune system and improving the effectiveness of immunotherapy in mice. The approach targets a protein that suppresses immune recognition, helping T cells detect and attack the tumor. This method could enhance immunotherapy for prostate cancer and other tumors that are typically resistant to treatment. The findings suggest a new strategy to overcome challenges in treating "immune cold" tumors.
Scientists used CRISPR to alter RNA in prostate cancer cells, making them more visible to the immune system and improving the effectiveness of immunotherapy in mice.
This breakthrough could lead to better treatments for prostate cancer and other "immune-cold" tumors that currently resist immunotherapy.
The research highlights a promising, targeted approach to cancer treatment that strengthens the body's natural defenses, offering hope for more effective and less harmful therapies.
upbeatBytes summarizes in its own words and links to the original publisher — it doesn't host the article.